Related Experiment Videos
[Interstitial lung disease linked to fluoxetine]
L M Vandezande1, C Lamblin, B Wallaert
1Service de Pneumologie et Immuno-allergologie, Hôpital Calmette, Lille.
Revue Des Maladies Respiratoires
|December 31, 1997
Summary
A patient developed interstitial pneumonia after nine months of fluoxetine (Prozac) treatment. Symptoms resolved after discontinuing the antidepressant, suggesting Prozac may cause drug-induced lung disease.
Area of Science:
- Pulmonology
- Pharmacology
- Toxicology
Background:
- Fluoxetine (Prozac), an antidepressant, has been available since 1989.
- Drug-induced lung disease is a potential adverse effect of various medications.
Observation:
- A patient presented with progressive dyspnea and bilateral basal crepitations after nine months of Prozac treatment.
- Clinical findings included inflammatory markers (ESR, CRP), interstitial lung disease on imaging, restrictive ventilatory defect, hypoxemia, and alveolar hyperlymphocytosis.
Findings:
- Pulmonary function tests revealed a restrictive ventilatory defect.
- Thoracic CT scan confirmed bilateral diffuse interstitial disease.
- Bronchoalveolar lavage showed hyperlymphocytosis, which normalized after Prozac cessation.
Implications:
- This case suggests a potential link between fluoxetine (Prozac) and drug-induced interstitial pneumonia.
- Discontinuation of Prozac led to clinical, radiological, and functional improvement.
- Further investigation into antidepressant-associated pulmonary toxicity is warranted.